| |
 |
|
|
Inventor: Higazi; Abd. Al-Roof
Address: Shimshon, IL
No. of patents: 4
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 7271143 |
Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and metho |
September 18, 2007 |
| Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolo |
| 7034006 |
Use of lipid conjugates in the treatment of disease |
April 25, 2006 |
| The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE |
| 6911316 |
Medical uses of scuPA/suPAR complex |
June 28, 2005 |
| Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a single chain urokinase type plasminogen activator (scuPA) and a soluble urokinase plasmino |
| 6759042 |
Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasmino |
July 6, 2004 |
| The present invention relates to the cross-linked scuPA/suPAR complex and/or tcuPA/suPAR cross-linked complex, the process of preparation of the covalently bound single compound having fibrinolytic activity and use of the cross-linked scuPA/suPAR or tcuPA/suPAR complex in the prevention |
|
|
|
